Investegate |F. Hoffmann-La Roche Ltd Announcements | F. Hof

Investegate announcements from F. Hoffmann-La Roche Ltd, CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

Related Keywords

United States , Japan , Switzerland , Canada , America , Nathalie Altermatt , Loren Kalm , Levi Garraway , Roche Group , European Commission , Health Canada , Head Of Global Product Development , Drug Administration , Roche Group Media Relations , Genentech , World Health Organization , European Medicines Agency , Medicinal Products , Human Use , Chief Medical Officer , Global Product , New England Journal , Fixed Duration Columvi , Biologics License Application , Dow Jones Sustainability Indices , Chugai Pharmaceutical , World Health , Cancer Incidence , Refractory Diffuse Largeb Cell , Investegate Announcements , Investegate Company Announcements , F Hoffmann La Roche Ltd , Lobenewswire , Lobenewswire And Globenewswire , Nw ,